95 / 164
225
REFERENCIAS BIBLIOGRáFICAS
1. Miller K, Foster C, Beck R, et al. Current State of Type 1
Diabetes Treatment in the U.S.: Updated Data From the T1D
Exchange Clinic Registry. Diabetes Care 2015;38:971–978.
2. Pozzilli P, Battelino T, Danne T, et al. Continuous subcutaneous
insulin infusion in diabetes: patient populations, safety,
efficacy, and pharmacoeconomics. Diabetes Metab Res Rev
2015. doi: 10.1002/dmrr.2653. [Epub ahead of print]
3. Grunberger G, Abelseth J, Bailey T, et al. Consensus Statement
by the American Association of Clinical Endocrinologists/
American College of Endocrinology Insulin Pump Management
Task Force. Endocr Pract 2014; 20 (5): 463-489.
4. Yeh H, Brown T, Marathur N, et al. Comparative Effectiveness
and Safety of Methods of Insulin Delivery and Glucose
Monitoring for Diabetes Mellitus A Systematic Review and
Meta-analysis. Ann Intern Med 2012;157:336-347.
5. Hill S, Sapir T. Methods for Insulin Delivery and Glucose
Monitoring in Diabetes: Summary of a Comparative
Effectiveness Review. Journal of Managed Care Pharmacy
2012; 18: S1-S17.
6. Hill S, Brown T, Yeh H, et al. Methods for Insulin Delivery and
Glucose Monitoring: Comparative Effectiveness. Agency for
Healthcare Research and Quality. Comparative Effectiveness
Review 2012; No. 57.
7. Sherr J, Hermann J, Campbell F, et al. Use of insulin pump
therapy in children and adolescents with type 1 diabetes and
its impact on metabolic control: comparison of results from
three large, transatlantic paediatric registries. Diabetologia
2015 Nov 7 [Epub ahead of print]; DOI 10.1007/s00125-
015-3790-6.
8. Bergenstal R, Klonoff D, Garg S, et al. Threshold-Based
Insulin-Pump Interruption for Reduction of Hypoglycemia. N
Engl J Med 2013;369:224-32.
9. L y T, Nicholas J, Retterath A, et al. Effect of Sensor-Augmented
Insulin Pump Therapy and Automated Insulin Suspension vs
Standard Insulin Pump Therapy on Hypoglycemia in Patients
With Type 1 Diabetes A Randomized Clinical Trial. JAMA.
2013;310(12):1240-1247.
10. Burdick J, Chase H, Slover R, et al. Missed insulin meal boluses
and elevated hemoglobin A1c levels in children receiving
insulin pump therapy. Pediatrics. 2004 Mar; 113:221-224.
11. Quirós C, Patrascioiu I, Giménez M, et al. Assessment of use
of specific features of subcutaneous insulin infusion systems
and their relationship to metabolic control in patients with
type 1 diabetes. Endocrinol Nutr. 2014; 61:318-322.
12. Admon G, Weinstein Y, Falk B, et al. Exercise With and Without
an Insulin Pump Among Children and Adolescents With Type
1 Diabetes Mellitus. Pediatrics. 2005; 116:348-355.
13. Gómez A, Gómez C, Aschner P, et al. Effects of Performing
Morning Versus Afternoon Exercise on Glycemic Control and
Hypoglycemia Frequency in Type 1 Diabetes Patients on
Sensor-Augmented Insulin Pump Therapy. J Diabetes Sci
Technol. 2015 May;9:619-624.
14. Franc S, Daoudi A, Pochat A, et al. Insulin-based strategies
to prevent hypoglycaemia during and after exercise in
adult patients with type 1 diabetes on pump therapy: the
DIABRASPORT randomized study. Diabetes, Obesity and
Metabolism 2015; 17: 1150–1157.
15. Barnard K, Chas T. Qualitative study into quality of life issues
surrounding insulin pump use in Type 1 diabetes. Practical
Diabetes 2007; 24 : 143-148.
16. De Vries L, Grushka Y, Lebenthal Y, et al. Factors associated
with increased risk of insulin pump discontinuation in
pediatric patients with type 1 diabetes. Pediatr Diabetes
2011; 12: 506-512.
17. Ross P, Milburn J, Reitch D, et al. Clinical review: insulin
pump-associated adverse events in adults and children. Acta
Diabetol 2015; 52(6):1017-1024.
18. Pickup J, Yemane N, Brackenridge A, et al. Nonmetabolic
Complications of Continuous Subcutaneous Insulin Infusion:
A Patient Survey. Diabetes Technol Ther. 2014;16:145-149.
19. Mecklenburg R, Benson E, Benson J, et al. Acute Complications
Associated With Insulin Infusion Pump Therapy Report of
Experience With 161 Patients. JAMA. 1984;252:3265-3269.
20. Wheeler B, Donaghue K, Heels K, et al.Family Perceptions of
Insulin Pump Adverse Events in Children and Adolescents.
Diabetes Technol Ther 2014, 16: 204-207.
21. Wheeler B, Heels K, Donaghue K, et al. Insulin Pump–Associated
Adverse Events in Children and Adolescents—A Prospective
Study. Diabetes Technol Ther 2014, 16(4): 558-562.
22. Scheen A, Castillo M, Jandrain B, et al. Metabolic alterations
after a two-hour nocturnal interruption of a continuous
subcutaneous insulin infusión. Diabetes Care. 1984; 7:338-
342.
23. Guerci B, Meyer L, Salle A, et al. Comparison of Metabolic
Deterioration between Insulin Analog and Regular Insulin
after a 5-Hour Interruption of a Continuous Subcutaneous
Insulin Infusion in Type 1 Diabetic Patients. J Clin Endocrinol
Metab. 1999; 84:2673-2678.
24. Realsen J, Goettle H, Chase P. Morbidity and Mortality of
Diabetic Ketoacidosis With and Without Insulin Pump Care.
Diabetes Technol Ther 2012, 14(12): 1149-1154.
25. Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of
continuous subcutaneous insulin infusion and multiple
daily injection regimens in children with type 1 diabetes: a
randomized open crossover trial. Pediatrics 2003; 112:559-
564.
26. St Charles M, Lynch P, Graham C, et al. A cost-effectiveness
analysis of continuous subcutaneous insulin injection versus
multiple daily injections in type 1 diabetes patients: a third-
party US payer perspective. Value Health. 2009; 12:674-
686.
27. Roze S, Valentine W, Zakrzewskat E; et al. Health-economic
comparison of continuous subcutaneous insulin infusion with
multiple daily injection for the treatment of Type 1 diabetes
in the UK. Diabetic Medicine 2005; 22: 1239–1245.
28. Cohen N, Minshall M, Sharon-Nash L, et al. Continuous
[NUEVAS TECNOLOGÍAS EN DIABETES - Dra. Ethel Codner y cols.]